BidaskClub Lowers Trevena (NASDAQ:TRVN) to Buy

BidaskClub downgraded shares of Trevena (NASDAQ:TRVN) from a strong-buy rating to a buy rating in a research report sent to investors on Thursday, BidAskClub reports.

Several other analysts have also issued reports on the stock. ValuEngine lowered shares of Trevena from a buy rating to a hold rating in a research report on Tuesday, June 23rd. Guggenheim initiated coverage on shares of Trevena in a research report on Monday, September 14th. They set a buy rating and a $5.00 price target for the company. Zacks Investment Research lowered shares of Trevena from a buy rating to a hold rating in a research report on Wednesday, October 7th. Cantor Fitzgerald initiated coverage on shares of Trevena in a research report on Thursday, August 27th. They set an overweight rating and a $5.00 price target for the company. Finally, HC Wainwright upped their price target on shares of Trevena from $4.00 to $5.00 and gave the company a buy rating in a research report on Tuesday, August 11th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $4.56.

TRVN opened at $2.94 on Thursday. The stock has a market cap of $386.99 million, a PE ratio of -10.50 and a beta of 2.83. The company has a quick ratio of 16.25, a current ratio of 16.25 and a debt-to-equity ratio of 0.13. Trevena has a 52 week low of $0.46 and a 52 week high of $3.68. The business’s fifty day simple moving average is $2.43 and its 200 day simple moving average is $1.67.

Trevena (NASDAQ:TRVN) last released its earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.06) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.06). As a group, equities analysts anticipate that Trevena will post -0.22 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of TRVN. Wedbush Securities Inc. purchased a new stake in shares of Trevena during the second quarter worth about $28,000. UBS Group AG boosted its holdings in shares of Trevena by 186.3% during the second quarter. UBS Group AG now owns 18,795 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 12,231 shares during the period. WINTON GROUP Ltd boosted its holdings in shares of Trevena by 11.4% during the second quarter. WINTON GROUP Ltd now owns 670,753 shares of the biopharmaceutical company’s stock worth $1,006,000 after purchasing an additional 68,538 shares during the period. IFP Advisors Inc boosted its holdings in shares of Trevena by 116.7% during the second quarter. IFP Advisors Inc now owns 21,674 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 11,674 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Trevena in the second quarter worth about $111,000. Institutional investors own 14.93% of the company’s stock.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain.

See Also: How to Use a Moving Average for TradingĀ 

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.